A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic monomyelocytic leukemia

Z Zhen Dong H Hugo Sepulveda (Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology) L Leo J. Arteaga-Vazquez (Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology) C Chad Blouin (Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology) J Jenna Fernandez (Division of Hematology, Department of Internal Medicine, Mayo Clinic) M Moritz Binder (Division of Hematology, Department of Internal Medicine, Mayo Clinic) W Wen-Chien Chou (Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital) H Hwei-Fang Tien (Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital) M Mrinal M. Patnaik (Division of Hematology, Department of Internal Medicine, Mayo Clinic) G Geoffrey J. Faulkner (Mater Research Institute - University of Queensland) S Samuel A. Myers A Anjana Rao

Abstract

ASXL transcriptional regulator 1 (ASXL1) is one of the three most frequently mutated genes in age-related clonal hematopoiesis (CH), alongside DNA methyltransferase 3 alpha (DNMT3A) and Tet methylcytosine dioxygenase 2 ( TET2) . CH can progress to myeloid malignancies including chronic monomyelocytic leukemia (CMML) and is also strongly associated with inflammatory cardiovascular disease and all-cause mortality in humans. DNMT3A and TET2 regulate DNA methylation and demethylation pathways, respectively, and loss-of-function mutations in these genes reduce DNA methylation in heterochromatin, allowing derepression of silenced elements in heterochromatin. In contrast, the mechanisms that connect mutant ASXL1 and CH are not yet fully understood. CH/CMML-associated ASXL1 mutations encode C-terminally truncated proteins that enhance the deubiquitinase activity of the ASXL-BAP1 “PR-DUB” deubiquitinase complex, which removes monoubiquitin from H2AK119Ub. Here, we show that ASXL1 mutant proteins interact with the euchromatic histone lysine methyltransferases 1 and 2 (EHMT1–EHMT2) complex, which generates H3K9me1 and me2, the latter a repressive modification in constitutive heterochromatin. Compared to cells from age-matched wild-type mice, we found that expanded myeloid cells from old (≥18-mo-old) Asxl1tm/+ mice, a heterozygous knock-in mouse model of CH, display genome-wide decreases of H3K9me2, H3K9me3, and H2AK119Ub as well as an associated increase in expression of transposable elements (TEs) and satellite repeats. Increased TE expression was also observed in monocytes from ASXL1 -mutant CMML patients compared to monocytes from healthy controls. Our data suggest that mutant ASXL1 proteins compromise the integrity of both constitutive and facultative heterochromatin in an age-dependent manner by reducing the levels of H3K9me2/3 and H2AK119Ub. This increase in TE expression correlated with increased expression of nearby genes, including many interferon-inducible (inflammation-associated) genes (ISGs).

Article Details

Volume / Issue Vol. 122, Issue 1
Published January 07, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

Z

Zhen Dong

H

Hugo Sepulveda

Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology

L

Leo J. Arteaga-Vazquez

Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology

C

Chad Blouin

Department of Signaling and Gene Expression, La Jolla Institute for Allergy and Immunology

J

Jenna Fernandez

Division of Hematology, Department of Internal Medicine, Mayo Clinic

M

Moritz Binder

Division of Hematology, Department of Internal Medicine, Mayo Clinic

W

Wen-Chien Chou

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital

H

Hwei-Fang Tien

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital

M

Mrinal M. Patnaik

Division of Hematology, Department of Internal Medicine, Mayo Clinic

G

Geoffrey J. Faulkner

Mater Research Institute - University of Queensland

S

Samuel A. Myers

A

Anjana Rao